(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.33%) $0.935
(0.54%) $11.01
(0.18%) $0.801
(0.00%) $92.17
@ $4.00
発行日: 14 2月 2024 @ 04:29
リターン: -40.25%
Live Chart Being Loaded With Signals
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues...
Stats | |
---|---|
本日の出来高 | 65 262.00 |
平均出来高 | 372 577 |
時価総額 | 4.69M |
EPS | $0 ( 2024-04-02 ) |
次の収益日 | ( $-3.33 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0200 |
ATR14 | $0.0500 (2.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-08 | Runge Jeffrey W. | Buy | 470 | Options (right to buy) |
2023-11-08 | Albanna Rowena | Buy | 4 702 | Options (right to buy) |
2023-11-08 | Nelson Charles Athle | Buy | 470 | Options (right to buy) |
2023-11-08 | Albanna Amro A. | Buy | 9 404 | Options (right to buy) |
2023-11-08 | Pankovcin Corinne | Buy | 4 702 | Options (right to buy) |
INSIDER POWER |
---|
26.52 |
Last 84 transactions |
Buy: 1 934 500 | Sell: 1 185 103 |
ボリューム 相関
ADiTx Therapeutics, Inc. 相関
10 最も負の相関 | |
---|---|
MSDA | -0.971 |
ADAL | -0.966 |
TIOAU | -0.961 |
TIOA | -0.961 |
BRIV | -0.96 |
LEGA | -0.959 |
ZING | -0.959 |
SKYA | -0.958 |
CRZN | -0.957 |
VLAT | -0.957 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
ADiTx Therapeutics, Inc. 相関 - 通貨/商品
ADiTx Therapeutics, Inc. 財務諸表
Annual | 2023 |
収益: | $645 176 |
総利益: | $-654 243 (-101.41 %) |
EPS: | $-107.10 |
FY | 2023 |
収益: | $645 176 |
総利益: | $-654 243 (-101.41 %) |
EPS: | $-107.10 |
FY | 2022 |
収益: | $933 715 |
総利益: | $166 936 (17.88 %) |
EPS: | $-608.04 |
FY | 2021 |
収益: | $105 034 |
総利益: | $27 055.00 (25.76 %) |
EPS: | $-6.72 |
Financial Reports:
No articles found.
ADiTx Therapeutics, Inc.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。